Literature DB >> 27068688

MANAGEMENT OF ENDOCRINE DISEASE: Epidemiology, quality of life and complications of primary adrenal insufficiency: a review.

Sophie Bensing1, Anna-Lena Hulting2, Eystein S Husebye3, Olle Kämpe4, Kristian Løvås3.   

Abstract

In this article, we review published studies covering epidemiology, natural course and mortality in primary adrenal insufficiency (PAI) or Addison's disease. Autoimmune PAI is a rare disease with a prevalence of 100-220 per million inhabitants. It occurs as part of an autoimmune polyendocrine syndrome in more than half of the cases. The patients experience impaired quality of life, reduced parity and increased risk of preterm delivery. Following a conventional glucocorticoid replacement regimen leads to a reduction in bone mineral density and an increase in the prevalence of fractures. Registry studies indicate increased mortality, especially evident in patients diagnosed with PAI at a young age and in patients with the rare disease autoimmune polyendocrine syndrome type-1. Most notably, unnecessary deaths still occur because of adrenal crises. All these data imply the need to improve the therapy and care of patients with PAI.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27068688     DOI: 10.1530/EJE-15-1242

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

1.  Adrenal crisis after first infusion of zoledronic acid: a case report.

Authors:  M Smrecnik; Z Kavcic Trsinar; T Kocjan
Journal:  Osteoporos Int       Date:  2018-03-28       Impact factor: 4.507

Review 2.  Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review.

Authors:  Laura Maria Mongioì; Rosita Angela Condorelli; Federica Barbagallo; Sandro La Vignera; Aldo Eugenio Calogero
Journal:  Endocrine       Date:  2020-01-11       Impact factor: 3.633

Review 3.  The potential role for infections in the pathogenesis of autoimmune Addison's disease.

Authors:  A Hellesen; E Bratland
Journal:  Clin Exp Immunol       Date:  2018-09-30       Impact factor: 4.330

4.  Lack of functional remission in Cushing's syndrome.

Authors:  M Vermalle; M Alessandrini; T Graillon; N C Paladino; K Baumstarck; F Sebag; H Dufour; T Brue; F Castinetti
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

Review 5.  Opioids and pituitary function: expert opinion.

Authors:  Mônica R Gadelha; Niki Karavitaki; Jeffrey Fudin; Jeffrey J Bettinger; Hershel Raff; Anat Ben-Shlomo
Journal:  Pituitary       Date:  2022-01-23       Impact factor: 4.107

6.  Addison's Disease and Dilated Cardiomyopathy: A Case Report and Review of the Literature.

Authors:  Viktoriya Mozolevska; Anna Schwartz; David Cheung; Bilal Shaikh; Kapil M Bhagirath; Davinder S Jassal
Journal:  Case Rep Cardiol       Date:  2016-11-28

7.  Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life.

Authors:  L M Mongioì; R A Condorelli; S La Vignera; A E Calogero
Journal:  Endocr Connect       Date:  2017-12-12       Impact factor: 3.335

8.  Characteristics of Korean Patients with Primary Adrenal Insufficiency: A Registry-Based Nationwide Survey in Korea.

Authors:  A Ram Hong; Ohk Hyun Ryu; Seong Yeon Kim; Sang Wan Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2017-12

9.  Heritability of Addison's disease and prevalence of associated autoimmunity in a cohort of 112,100 Swedish twins.

Authors:  Jakob Skov; Jonas Höijer; Patrik K E Magnusson; Jonas F Ludvigsson; Olle Kämpe; Sophie Bensing
Journal:  Endocrine       Date:  2017-10-16       Impact factor: 3.633

10.  Significant barriers to diagnosis and management of adrenal insufficiency in Africa.

Authors:  Thabiso R P Mofokeng; Salem A Beshyah; Fazleh Mahomed; Kwazi C Z Ndlovu; Ian L Ross
Journal:  Endocr Connect       Date:  2020-05       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.